Changing Treatment Paradigms in Heavily Pre-Treated RRMM Patients

Changing Treatment Paradigms in Heavily Pre-Treated RRMM Patients
Changing Treatment Paradigms in Heavily Pre-Treated RRMM Patients
CME, CPE
Sagar Lonial, MD, FACP
Release Date: May 20, 2020
Expiration Date: May 20, 2021

Treating patients with relapsed/refractory multiple myeloma (RRMM) has become more challenging with the introduction of new agents. In this activity, Dr. Lonial discusses the management of RRMM, given the new number of agents available, and which options are the best choice at the different stages of care. He will also review disease-related factors, treatment-related factors, and patient-related factors when considering treatment selection.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
Begin, Earn CreditView Only, No CreditGet Certificate